ArticleInsights into imaging2025
Performance of image-guided bone biopsies in malignant lesions: impact of PET/CT metabolic activity on the number of samples required.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of the present study is to determine whether or not lesion characteristics on PET/CT could reduce the number of samples required to achieve a diagnosis in image-guided bone biopsies (IGBB). MATERIALS AND
methodsA retrospective review of 38 percutaneous IGBB performed at a single center. Biopsies have been performed from January 1st, 2020, to October 23rd, 2024. Inclusion criteria were patients with a PET/CT and a histopathologic report available. Specimens were collected, numbered, and independently analyzed in separate containers. PET/CT data, including SUV
resultsThirty-four/38 (89%) involved spinal and pelvic locations (34/38; 89%). Breast cancer metastases were the most common diagnosis (21/38; 55%). Group 1 included 20 IGBB (52%), group 2 included 9 IGBB (24%), and group 3 included 9 IGBB (24%). No statistically significant difference was found between groups in metabolic characteristics and the number of samples needed for diagnostic purposes (p > 0.05). Subgroup analysis, including factors such as density or lesion size, didn't find any significant differences between groups.
conclusionThe results suggest that high metabolic activity alone does not justify reducing the number of biopsy samples without compromising diagnostic performance. This supports the recommendation to obtain at least three samples and highlights the importance of selecting the safest biopsy site, regardless of metabolic activity. CRITICAL RELEVANCE STATEMENT: This study critically assesses the role of FDG PET/CT metabolic parameters in predicting the diagnostic success of IGBB, providing new insights to improve target selection and biopsy planning in clinical radiology. KEY POINTS: This study assessed whether metabolic activity on FDG PET/CT influences the diagnostic yield of IGBB. High metabolic activity did not allow for reducing the number of samples without affecting diagnostic performance. At least three biopsy samples should be obtained, prioritizing safety over metabolic activity when selecting the biopsy site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.